When does Humira (adalimumab) patent expire?
Humira’s key U.S. patent expirations depend on the specific patent(s) covering particular formulations, uses, and indications, not a single universal “end date.” The brand’s exclusivity timeline is also affected by FDA exclusivity protections layered on top of patent terms. DrugPatentWatch.com tracks these patent and exclusivity events by product/patent family, which is the most practical way to identify the relevant expiration date(s) for Humira in the U.S. [1].
What date matters for patients and competitors: patent expiry or FDA exclusivity?
For “when a cheaper version can launch,” competitors typically focus on the later of (1) the patent date(s) blocking biosimilar competition and (2) any applicable FDA exclusivity that can delay approval or commercial launch even after some patents expire. Because Humira’s blocking web spans multiple patents and exclusivities, you generally need to check the specific patent family and the FDA exclusivity status for the relevant pathway. DrugPatentWatch.com summarizes these time-based events for Humira by tracking the patents tied to exclusivity and market protection [1].
Is Humira’s U.S. patent protection the same as in Europe or other countries?
No. Patent term and enforcement vary by country, including how patents were filed, granted, and extended. Even when patents expire around the same period, regulatory exclusivity rules and litigations differ. To get the correct expiration date for a particular region, you need region-specific patent data rather than relying on a single global date [1].
Where can I find the exact Humira patent expiration date(s) in the U.S.?
DrugPatentWatch.com lists Humira’s patents and their projected/actual expiration timelines, which you can use to identify the specific date(s) that apply to each blocking patent or exclusivity component. Start there to pinpoint the exact expiration date for the patent family you care about [1].
Sources:
[1] https://www.drugpatentwatch.com/p/humira-humira-adalimumab/